Myelofibrosis (MF) Treatment Market
Market Insights on Myelofibrosis (MF) Treatment covering sales outlook, demand forecast & up-to-date key trends
Myelofibrosis (MF) Treatment Market by Types, Route of Administration, End-Users, Distribution Channels, & Regional forecast till 2033?
Myelofibrosis (MF) Treatment Market Snapshot (2023-2033)
The global myelofibrosis (MF) treatment market is expected to reach at US$ 749.05 Million in 2023 and is projected to exhibit a CAGR of 5.5% from 2023 to 2033. MF is becoming more prevalent around the globe and early diagnosis is driving market growth. Also, the increasing emphasis on R&D activity by key players will create lucrative opportunities for Myelofibrosis (MF) Treatment market growth.
Myelofibrosis is characterized by the presence of proteins called Janus-associated kinases (JAKs). There will also be an overview of emerging JAK inhibitor therapy as well as non-JAK inhibitor therapy which will also be focused, along with the new challenge of switching from one JAK inhibitor therapy to another. Future therapies within this field are highly anticipated and new JAK inhibitor and non-JAK inhibitor therapies will also be discussed.
The treatment goals are typically to reduce splenomegaly and disease-associated symptoms, decrease complications such as thrombosis and hemorrhaging, and ideally slow disease progression. As the number of available agents for myelofibrosis management has increased in the past decade, therapeutic strategies mainly focus on symptom management.
|
Data Points |
Key Statistics |
|
Estimated Base Year Value (2022) |
US$ 712 Million |
|
Expected Market Value (2023) |
US$ 749.05 Million |
|
Anticipated Forecast Value (2033) |
US$ 1,280 Million |
|
Projected Growth Rate (2023-2033) |
5.5% CAGR |
Let us know your requirement to get
100% FREE customization
2018-2022 Myelofibrosis Demand Analysis vs. Forecast 2023-2033
The global demand for myelofibrosis is projected to increase at a CAGR of 5.5% during the forecast period between 2023 and 2033, reaching a total of US$ 1,280 Million in 2033, according to a report from Future Market Insights (FMI). From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 5.2%.
The growth in awareness regarding Myelofibrosis (MF) Treatment and the rise in the number of patients are also predicted to result in a rise in the number of products specifically related to the disease being produced during the forecast period of 2023 to 2032. In view of the complicated reimbursement associated with multiple patent expirations, the market for Myelofibrosis (MF) Treatment is projected to grow at a moderate pace throughout the forecast period. Myelofibrosis researchers worldwide are exploring strategies for treating and managing side effects of treatment.
Ruxolitinib, an oral JAK1/JAK2 inhibitor and the only approved therapy for MF, is a potent oral JAK1/JAK2 inhibitor with clinical data, and agents in development are being studied. Patients with myelofibrosis can choose from a variety of treatment options based on their symptoms and circumstances. Furthermore, the onset of several diseases has led to the introduction of several drugs intended to reduce blood volume and relieve symptoms of the various diseases.
Factors Driving the Global Myelofibrosis Treatments Market
Developing New Therapies Received a Major Boost During the Pandemic Crisis
Due to the increasing prevalence of various genetic disorders and the improvement in lifestyle choices, myelofibrosis treatment market is expected to grow. Myelofibrosis treatment market revenue growth is expected to be driven by an increase in the number of smokers in the world, which will support revenue growth. Additionally, government investments are expected to increase in the healthcare infrastructure, especially in developing countries, which is expected to boost revenue growth.
Globally, increasing geriatric populations and new diagnostic tools are contributing to the increase in treatment options for myelofibrosis, which most commonly occurs to people over 50. The increase in anemic conditions and splenomegaly is further expected to result in a further increase in the market conditions in the future. In addition to exposure to industrial chemicals and radiation, myelofibrosis is also associated with thrombocythemia and polycythemia vera. Therefore, these risk factors are becoming more prevalent among significant parts of the population, which drives market development.
Pipeline Drugs Seeking FDA Approval will drive Market Growth
Idiopathic myelofibrosis is becoming more prevalent in developing economies, resulting in the need for different treatment options. Investing heavily in R&D, implementing favorable reimbursement policies, and having a large pool of myelofibrosis patients are factors that are causing the market to grow. As a result of the lack of treatment options, there is an urgent need for medical treatment for this disease.
With the medical advancements focusing on patients suffering from myelofibrosis, the market is expected to gain significant traction. For instance, Gilead Sciences developed the drug CYT387, or momelotinib, to treat primary myelofibrosis, and Incyte Corporation developed an alternative dosing strategy for the current drug ruxolitinib.
Another instance, a drug called pacritinib (Vonjo) has been approved by the Food and Drug Administration (FDA) for patients suffering from Myelofibrosis (MF) Treatment, a rare blood cancer that damages normal red blood cells. Due to its suitability for patients with severely low platelet counts, pacritinib should fill an important treatment gap since it is not as toxic as the other two drugs approved to treat AD, ruxolitinib (Jakafi) and fedratinib (Inrebic).
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystWhat are the Barriers to Myelofibrosis Treatment in the Market?
Delay in Diagnosis of Myelofibrosis Symptoms Impedes the Growth of the Patient?
Genetic mutations in stem cells in the bone marrow cause myelofibrosis. A majority of people with the disorder are over the age of 50 and don't show any symptoms early on. This will hamper the growth of the market.
Currently, the global myelofibrosis market is not experiencing revenue growth due to the lack of awareness regarding myelofibrosis disease and the high costs associated with treatment. Furthermore, in the near future, the side effects associated with myelofibrosis treatment drugs are expected to dampen market growth.
Country-Wise Insights
Why is North America the Biggest Market for Myelofibrosis Treatment?
Reimbursement Policies will increase Treatment Adoption for Myelofibrosis
Having a well-established healthcare system and a high awareness of cancer patients, North America is expected to hold 53% of the global healthcare market in 2023. This region is experiencing significant growth due to one of the fastest growing diseases in the world, increased awareness about its manifestations, and reasonable reimbursement conditions in comparison with other economies.
Myelofibrosis prevalence in the United States was 19,815 cases in 2021, with the rate expected to climb during the study period, which is 2019-2032. Increasing funding for research and healthcare infrastructure in the region is expected to contribute to North America dominate the global market for myelofibrosis. As a result of higher healthcare spending, favorable reimbursement conditions and favorable reimbursement rates, the region has prospered.
What is the Scope for Myelofibrosis Treatment in Europe?
Growing Cancer Treatment Facilities are resulting in a Rise in Myelofibrosis Treatment
The European region is expected to dominate the global market for myelofibrosis treatments with a market share of 42% during the forecast period. With more government approvals for treatment and devices on the market, the demand for myelofibrosis treatment is expected to expand. For instance, the European Medicines Agency has approved momelotinib's marketing authorization application for myelofibrosis. Momelotinib, a novel treatment for myelofibrosis, has been approved by the European Medicines Agency (EMA) on the basis of data from the phase 3 MOMENTUM trial (NCT04173494).
As a result of ongoing research and the availability of advanced treatments, it is anticipated that the market will continue to grow. For instance, Imago BioSciences, Inc., as part of its ongoing Phase 2 clinical study evaluating bomedemstat in patients with advanced Myelofibrosis (MF) Treatment, a biopharmaceutical company that discovers and develops new medicines against blood cancers and other bone marrow disorders revealed positive results.
Furthermore, the National Institute of Health (NIH) lists myelofibrosis as a rare disease since there are about 0.5 cases per 100,000 people in the UK. As disposable incomes and spending capacities increase, the market is expected to grow further.
A unified Market Research Subscription Platform, built for today's disparate research needs.
Category-wise Insights
How are Chemotherapy Treatments Impacting the Growth of the Myelofibrosis Market?
Increasing Number of Cancer Patients Will Increase Growth at a Significant Rate
Based on treatment type of myelofibrosis treatment the market for chemotherapy is expected to grow the market. Chemotherapy drug market growth is expected to be boosted by rising cancer prevalence. Growth in healthcare expenditure also contributes to the growth of the chemotherapy market. Governments are also endeavoring to improve the healthcare infrastructure by increasing government funds available to the industry, and this will further impact the dynamics of the market.
A growing market for chemotherapy products will also be driven by the expansion of emerging markets and the introduction of novel products in the future. The recent approval of chemotherapeutics will play a significant role in the growth of the chemotherapy treatment market over the forecast period. The increasing prevalence of chemotherapy-induced myelofibrosis and the improvement in access to the treatment have made chemotherapy-induced myelofibrosis a great opportunity for developing countries to generate revenue from the disease. As a result of all these factors, the market for myelofibrosis chemotherapy treatment and drug development is expected to grow.
How Do Oral Medications Have the Potential to Boost the Market for Myelofibrosis?
Demand for myelofibrosis treatment in Hospital and Wound Care Centers to Gain Traction
Based on route of administration, the global market is segmented into oral, parenteral, others. Oral route of administration is expected to grow at a revenue share of 38% during the forecast period. Drug routes for treating cancer have propelled great awareness and adaption in the market. FDA recently approved the first drug specifically for patients with severely low platelet counts (thrombocytopenia) in the management of myelofibrosis with intermediate or high risk (thrombocytopenia).
Several technologies have improved the development of drugs for myelobibrosis on the market, as well as FDA-approved drugs on the market. For instance, AbbVie Inc., released new data from its Phase 2 trial of navitoclax with ruxolitinib. A presentation of the findings was made at the annual meeting of the American Association for Cancer Research 2022 (AACR 2022, abstract #LB108). First-of-its-kind, Navitoclax inhibits BCL-XL/BCL-2 in cancer cells via oral apoptosis (programmed cell death).
The Start-Up Ecosystem: What are Start-Ups Doing to Secure Future Growth Opportunities?
Some of the start-ups in the myelofibrosis treatment market?include-?
- Myeloid Therapeutics: Therapeutics solutions are developed by Myeloid to treat cancer and other diseases. Myeloid cells containing CARs are activated by the company's ATAK platform, which triggers tumor-specific phagocytosis and secretions of proinflammatory cytokines, which help kill tumor cells. After successfully completing in vitro and animal studies, the technology is in the preclinical stage.
- Sierra Oncology: Develops targeted therapies for cancer treatment. In addition to Momelotinib, myelofibrosis is treated with ACVR1 inhibitors, JAK1 & JAK2 inhibitors. Solid tumors and heme malignancies are also candidates for SRA515.
- Orsenix, a U.S. based start-up. Biotechnology company developing cancer therapeutics. In addition to ORH-2014, the company offers a treatment for acute promyelocytic leukemia (APL). Arsenic trioxide (ATO) is a capsule form that can be taken orally. Besides treating myeloid cancers, ATO is also being developed in order to treat myeloid disorders, such as myelodysplastic syndromes, myelofibrosis, and glioblastoma.
Market Competition
Strategic partnerships can boost revenue and market share for manufacturers by increasing production and meeting consumer demand. End users will benefit from the use of new products and technologies by promoting them. Strategic partnerships can be formed by companies in order to increase their production capacity.
- An investigational selective oral PIM1 kinase inhibitor, TP-354, presented new data from Sumitomo Pharma Oncology, Inc., a company specializing in novel cancer therapeutics. In patients previously treated with or ineligible for JAK inhibitor therapy or ineligible for JAK inhibitor therapy, TP-3654 is an investigational selective oral PIM1 kinase inhibitor. A presentation of these results will be made at the 2022 American Society of Hematology's Annual Meeting & Exposition in New Orleans, LA, from December 10-13, 2022.
- Myeloproliferative neoplasms (MPNs) and other bone marrow diseases are treated by Imago BioSciences, Inc., a clinical-stage biopharmaceutical company, announced that the first experimental drug (methotrexate) and ruxolitinib (Jakafi®) has been administered to a patient with MF.). In the United States, ruxolitinib is approved by the Food and Drug Administration (FDA) for multiple indications, including the treatment of intermediate or high-risk MF.
Report Scope
|
Report Attribute |
Details |
|
Market Value in 2023 |
US$ 749.05 Million |
|
Market Value in 2033 |
US$ 1,280 Million |
|
Growth Rate |
CAGR 5.5% |
|
Base Year for Estimation |
2022 |
|
Historical Data |
2018-2022 |
|
Forecast Period |
2023-2033 |
|
Quantitative Units |
Revenue in US$ Billion and CAGR from 2023-2033 |
|
Report Coverage |
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
|
Segments Covered |
|
|
Regions Covered |
|
|
Key Countries Profiled |
|
|
Key Companies Profiled |
|
|
Customization |
Available Upon Request |
Key Segments Profiled in the Myelofibrosis Market Industry Survey?
By Treatment Type:
- Targeted Therapy
- Chemotherapy
- Others
By Route of Administration:
- Oral
- Parenteral
- Others
By End User:
- Hospitals
- Homecare
- Specialty Clinics
- Others
By Distribution Channel:
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East & Africa
Frequently Asked Questions
FMI projects the global myelofibrosis market to expand at a 5.5% value CAGR by 2033.
The global myelofibrosis market is estimated at a market value of US$ 749.05 Million.
The global myelofibrosis market is expected to garner a market value of US$ 1,280 Million.
North America is expected to hold 53% of the myelofibrosis market.
Pfizer Inc., F. Hoffmann-La Roche Ltd., Mylan N.V. and Fresenius Kabi AG are some prominent myelofibrosis manufacturers in the market.
Oral route of administration market will hold 33% of the market value in 2023.
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018-2022 and Forecast, 2023-2033
4.1. Historical Market Size Value (US$ Mn) Analysis, 2018-2022
4.2. Current and Future Market Size Value (US$ Mn) Projections, 2023-2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Treatment Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Mn) Analysis By Treatment Type, 2018-2022
5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Treatment Type, 2023-2033
5.3.1. Targeted Therapy
5.3.2. Chemotherapy
5.3.3. Others
5.4. Y-o-Y Growth Trend Analysis By Treatment Type, 2018-2022
5.5. Absolute $ Opportunity Analysis By Treatment Type, 2023-2033
6. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Route of Administration
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Mn) Analysis By Route of Administration, 2018-2022
6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Route of Administration, 2023-2033
6.3.1. Oral
6.3.2. Parenteral
6.3.3. Others
6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018-2022
6.5. Absolute $ Opportunity Analysis By Route of Administration, 2023-2033
7. Global Market Analysis 2018-2022 and Forecast 2023-2033, By End-Users
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Mn) Analysis By End-Users , 2018-2022
7.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By End-Users , 2023-2033
7.3.1. Hospitals
7.3.2. Homecare
7.3.3. Specialty Clinics
7.3.4. Others
7.4. Y-o-Y Growth Trend Analysis By End-Users , 2018-2022
7.5. Absolute $ Opportunity Analysis By End-Users , 2023-2033
8. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Distribution Channel
8.1. Introduction / Key Findings
8.2. Historical Market Size Value (US$ Mn) Analysis By Distribution Channel, 2018-2022
8.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Distribution Channel, 2023-2033
8.3.1. Hospital Pharmacy
8.3.2. Online Pharmacy
8.3.3. Retail Pharmacy
8.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018-2022
8.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023-2033
9. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Region
9.1. Introduction
9.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2018-2022
9.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2023-2033
9.3.1. North America
9.3.2. Latin America
9.3.3. Europe
9.3.4. South Asia
9.3.5. East Asia
9.3.6. Oceania
9.3.7. MEA
9.4. Market Attractiveness Analysis By Region
10. North America Market Analysis 2018-2022 and Forecast 2023-2033, By Country
10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022
10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033
10.2.1. By Country
10.2.1.1. U.S.
10.2.1.2. Canada
10.2.2. By Treatment Type
10.2.3. By Route of Administration
10.2.4. By End-Users
10.2.5. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Treatment Type
10.3.3. By Route of Administration
10.3.4. By End-Users
10.3.5. By Distribution Channel
10.4. Key Takeaways
11. Latin America Market Analysis 2018-2022 and Forecast 2023-2033, By Country
11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022
11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033
11.2.1. By Country
11.2.1.1. Brazil
11.2.1.2. Mexico
11.2.1.3. Rest of Latin America
11.2.2. By Treatment Type
11.2.3. By Route of Administration
11.2.4. By End-Users
11.2.5. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Treatment Type
11.3.3. By Route of Administration
11.3.4. By End-Users
11.3.5. By Distribution Channel
11.4. Key Takeaways
12. Europe Market Analysis 2018-2022 and Forecast 2023-2033, By Country
12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022
12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033
12.2.1. By Country
12.2.1.1. Germany
12.2.1.2. U.K.
12.2.1.3. France
12.2.1.4. Spain
12.2.1.5. Italy
12.2.1.6. Rest of Europe
12.2.2. By Treatment Type
12.2.3. By Route of Administration
12.2.4. By End-Users
12.2.5. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Treatment Type
12.3.3. By Route of Administration
12.3.4. By End-Users
12.3.5. By Distribution Channel
12.4. Key Takeaways
13. South Asia Market Analysis 2018-2022 and Forecast 2023-2033, By Country
13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022
13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033
13.2.1. By Country
13.2.1.1. India
13.2.1.2. Malaysia
13.2.1.3. Singapore
13.2.1.4. Thailand
13.2.1.5. Rest of South Asia
13.2.2. By Treatment Type
13.2.3. By Route of Administration
13.2.4. By End-Users
13.2.5. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Treatment Type
13.3.3. By Route of Administration
13.3.4. By End-Users
13.3.5. By Distribution Channel
13.4. Key Takeaways
14. East Asia Market Analysis 2018-2022 and Forecast 2023-2033, By Country
14.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022
14.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033
14.2.1. By Country
14.2.1.1. China
14.2.1.2. Japan
14.2.1.3. South Korea
14.2.2. By Treatment Type
14.2.3. By Route of Administration
14.2.4. By End-Users
14.2.5. By Distribution Channel
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Treatment Type
14.3.3. By Route of Administration
14.3.4. By End-Users
14.3.5. By Distribution Channel
14.4. Key Takeaways
15. Oceania Market Analysis 2018-2022 and Forecast 2023-2033, By Country
15.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022
15.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033
15.2.1. By Country
15.2.1.1. Australia
15.2.1.2. New Zealand
15.2.2. By Treatment Type
15.2.3. By Route of Administration
15.2.4. By End-Users
15.2.5. By Distribution Channel
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Treatment Type
15.3.3. By Route of Administration
15.3.4. By End-Users
15.3.5. By Distribution Channel
15.4. Key Takeaways
16. MEA Market Analysis 2018-2022 and Forecast 2023-2033, By Country
16.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022
16.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033
16.2.1. By Country
16.2.1.1. GCC Countries
16.2.1.2. South Africa
16.2.1.3. Israel
16.2.1.4. Rest of MEA
16.2.2. By Treatment Type
16.2.3. By Route of Administration
16.2.4. By End-Users
16.2.5. By Distribution Channel
16.3. Market Attractiveness Analysis
16.3.1. By Country
16.3.2. By Treatment Type
16.3.3. By Route of Administration
16.3.4. By End-Users
16.3.5. By Distribution Channel
16.4. Key Takeaways
17. Key Countries Market Analysis
17.1. U.S.
17.1.1. Pricing Analysis
17.1.2. Market Share Analysis, 2022
17.1.2.1. By Treatment Type
17.1.2.2. By Route of Administration
17.1.2.3. By End-Users
17.1.2.4. By Distribution Channel
17.2. Canada
17.2.1. Pricing Analysis
17.2.2. Market Share Analysis, 2022
17.2.2.1. By Treatment Type
17.2.2.2. By Route of Administration
17.2.2.3. By End-Users
17.2.2.4. By Distribution Channel
17.3. Brazil
17.3.1. Pricing Analysis
17.3.2. Market Share Analysis, 2022
17.3.2.1. By Treatment Type
17.3.2.2. By Route of Administration
17.3.2.3. By End-Users
17.3.2.4. By Distribution Channel
17.4. Mexico
17.4.1. Pricing Analysis
17.4.2. Market Share Analysis, 2022
17.4.2.1. By Treatment Type
17.4.2.2. By Route of Administration
17.4.2.3. By End-Users
17.4.2.4. By Distribution Channel
17.5. Germany
17.5.1. Pricing Analysis
17.5.2. Market Share Analysis, 2022
17.5.2.1. By Treatment Type
17.5.2.2. By Route of Administration
17.5.2.3. By End-Users
17.5.2.4. By Distribution Channel
17.6. U.K.
17.6.1. Pricing Analysis
17.6.2. Market Share Analysis, 2022
17.6.2.1. By Treatment Type
17.6.2.2. By Route of Administration
17.6.2.3. By End-Users
17.6.2.4. By Distribution Channel
17.7. France
17.7.1. Pricing Analysis
17.7.2. Market Share Analysis, 2022
17.7.2.1. By Treatment Type
17.7.2.2. By Route of Administration
17.7.2.3. By End-Users
17.7.2.4. By Distribution Channel
17.8. Spain
17.8.1. Pricing Analysis
17.8.2. Market Share Analysis, 2022
17.8.2.1. By Treatment Type
17.8.2.2. By Route of Administration
17.8.2.3. By End-Users
17.8.2.4. By Distribution Channel
17.9. Italy
17.9.1. Pricing Analysis
17.9.2. Market Share Analysis, 2022
17.9.2.1. By Treatment Type
17.9.2.2. By Route of Administration
17.9.2.3. By End-Users
17.9.2.4. By Distribution Channel
17.10. India
17.10.1. Pricing Analysis
17.10.2. Market Share Analysis, 2022
17.10.2.1. By Treatment Type
17.10.2.2. By Route of Administration
17.10.2.3. By End-Users
17.10.2.4. By Distribution Channel
17.11. Malaysia
17.11.1. Pricing Analysis
17.11.2. Market Share Analysis, 2022
17.11.2.1. By Treatment Type
17.11.2.2. By Route of Administration
17.11.2.3. By End-Users
17.11.2.4. By Distribution Channel
17.12. Singapore
17.12.1. Pricing Analysis
17.12.2. Market Share Analysis, 2022
17.12.2.1. By Treatment Type
17.12.2.2. By Route of Administration
17.12.2.3. By End-Users
17.12.2.4. By Distribution Channel
17.13. Thailand
17.13.1. Pricing Analysis
17.13.2. Market Share Analysis, 2022
17.13.2.1. By Treatment Type
17.13.2.2. By Route of Administration
17.13.2.3. By End-Users
17.13.2.4. By Distribution Channel
17.14. China
17.14.1. Pricing Analysis
17.14.2. Market Share Analysis, 2022
17.14.2.1. By Treatment Type
17.14.2.2. By Route of Administration
17.14.2.3. By End-Users
17.14.2.4. By Distribution Channel
17.15. Japan
17.15.1. Pricing Analysis
17.15.2. Market Share Analysis, 2022
17.15.2.1. By Treatment Type
17.15.2.2. By Route of Administration
17.15.2.3. By End-Users
17.15.2.4. By Distribution Channel
17.16. South Korea
17.16.1. Pricing Analysis
17.16.2. Market Share Analysis, 2022
17.16.2.1. By Treatment Type
17.16.2.2. By Route of Administration
17.16.2.3. By End-Users
17.16.2.4. By Distribution Channel
17.17. Australia
17.17.1. Pricing Analysis
17.17.2. Market Share Analysis, 2022
17.17.2.1. By Treatment Type
17.17.2.2. By Route of Administration
17.17.2.3. By End-Users
17.17.2.4. By Distribution Channel
17.18. New Zealand
17.18.1. Pricing Analysis
17.18.2. Market Share Analysis, 2022
17.18.2.1. By Treatment Type
17.18.2.2. By Route of Administration
17.18.2.3. By End-Users
17.18.2.4. By Distribution Channel
17.19. GCC Countries
17.19.1. Pricing Analysis
17.19.2. Market Share Analysis, 2022
17.19.2.1. By Treatment Type
17.19.2.2. By Route of Administration
17.19.2.3. By End-Users
17.19.2.4. By Distribution Channel
17.20. South Africa
17.20.1. Pricing Analysis
17.20.2. Market Share Analysis, 2022
17.20.2.1. By Treatment Type
17.20.2.2. By Route of Administration
17.20.2.3. By End-Users
17.20.2.4. By Distribution Channel
17.21. Israel
17.21.1. Pricing Analysis
17.21.2. Market Share Analysis, 2022
17.21.2.1. By Treatment Type
17.21.2.2. By Route of Administration
17.21.2.3. By End-Users
17.21.2.4. By Distribution Channel
18. Market Structure Analysis
18.1. Competition Dashboard
18.2. Competition Benchmarking
18.3. Market Share Analysis of Top Players
18.3.1. By Regional
18.3.2. By Treatment Type
18.3.3. By Route of Administration
18.3.4. By End-Users
18.3.5. By Distribution Channel
19. Competition Analysis
19.1. Competition Deep Dive
19.1.1. Pfizer Inc.
19.1.1.1. Overview
19.1.1.2. Product Portfolio
19.1.1.3. Profitability by Market Segments
19.1.1.4. Sales Footprint
19.1.1.5. Strategy Overview
19.1.1.5.1. Marketing Strategy
19.1.2. F. Hoffmann-La Roche Ltd
19.1.2.1. Overview
19.1.2.2. Product Portfolio
19.1.2.3. Profitability by Market Segments
19.1.2.4. Sales Footprint
19.1.2.5. Strategy Overview
19.1.2.5.1. Marketing Strategy
19.1.3. Mylan N.V.
19.1.3.1. Overview
19.1.3.2. Product Portfolio
19.1.3.3. Profitability by Market Segments
19.1.3.4. Sales Footprint
19.1.3.5. Strategy Overview
19.1.3.5.1. Marketing Strategy
19.1.4. Fresenius Kabi AG
19.1.4.1. Overview
19.1.4.2. Product Portfolio
19.1.4.3. Profitability by Market Segments
19.1.4.4. Sales Footprint
19.1.4.5. Strategy Overview
19.1.4.5.1. Marketing Strategy
19.1.5. Hikma Pharmaceuticals PLC
19.1.5.1. Overview
19.1.5.2. Product Portfolio
19.1.5.3. Profitability by Market Segments
19.1.5.4. Sales Footprint
19.1.5.5. Strategy Overview
19.1.5.5.1. Marketing Strategy
19.1.6. Novartis AG
19.1.6.1. Overview
19.1.6.2. Product Portfolio
19.1.6.3. Profitability by Market Segments
19.1.6.4. Sales Footprint
19.1.6.5. Strategy Overview
19.1.6.5.1. Marketing Strategy
19.1.7. Teva Pharmaceutical Industries Ltd.
19.1.7.1. Overview
19.1.7.2. Product Portfolio
19.1.7.3. Profitability by Market Segments
19.1.7.4. Sales Footprint
19.1.7.5. Strategy Overview
19.1.7.5.1. Marketing Strategy
19.1.8. Bristol Myers Squibb Company
19.1.8.1. Overview
19.1.8.2. Product Portfolio
19.1.8.3. Profitability by Market Segments
19.1.8.4. Sales Footprint
19.1.8.5. Strategy Overview
19.1.8.5.1. Marketing Strategy
19.1.9. GSK Plc.
19.1.9.1. Overview
19.1.9.2. Product Portfolio
19.1.9.3. Profitability by Market Segments
19.1.9.4. Sales Footprint
19.1.9.5. Strategy Overview
19.1.9.5.1. Marketing Strategy
19.1.10. Bayer AG
19.1.10.1. Overview
19.1.10.2. Product Portfolio
19.1.10.3. Profitability by Market Segments
19.1.10.4. Sales Footprint
19.1.10.5. Strategy Overview
19.1.10.5.1. Marketing Strategy
19.1.11. Sun Pharmaceutical Industries Ltd
19.1.11.1. Overview
19.1.11.2. Product Portfolio
19.1.11.3. Profitability by Market Segments
19.1.11.4. Sales Footprint
19.1.11.5. Strategy Overview
19.1.11.5.1. Marketing Strategy
19.1.12. Boehringer Ingelheim International Gmbh
19.1.12.1. Overview
19.1.12.2. Product Portfolio
19.1.12.3. Profitability by Market Segments
19.1.12.4. Sales Footprint
19.1.12.5. Strategy Overview
19.1.12.5.1. Marketing Strategy
19.1.13. Sanofi
19.1.13.1. Overview
19.1.13.2. Product Portfolio
19.1.13.3. Profitability by Market Segments
19.1.13.4. Sales Footprint
19.1.13.5. Strategy Overview
19.1.13.5.1. Marketing Strategy
20. Assumptions & Acronyms Used
21. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 1: Global Market Value (US$ Mn) Forecast by Region, 2018-2033
Table 2: Global Market Value (US$ Mn) Forecast by Treatment Type, 2018-2033
Table 3: Global Market Value (US$ Mn) Forecast by Route of Administration, 2018-2033
Table 4: Global Market Value (US$ Mn) Forecast by End-Users , 2018-2033
Table 5: Global Market Value (US$ Mn) Forecast by Distribution Channel, 2018-2033
Table 6: North America Market Value (US$ Mn) Forecast by Country, 2018-2033
Table 7: North America Market Value (US$ Mn) Forecast by Treatment Type, 2018-2033
Table 8: North America Market Value (US$ Mn) Forecast by Route of Administration, 2018-2033
Table 9: North America Market Value (US$ Mn) Forecast by End-Users , 2018-2033
Table 10: North America Market Value (US$ Mn) Forecast by Distribution Channel, 2018-2033
Table 11: Latin America Market Value (US$ Mn) Forecast by Country, 2018-2033
Table 12: Latin America Market Value (US$ Mn) Forecast by Treatment Type, 2018-2033
Table 13: Latin America Market Value (US$ Mn) Forecast by Route of Administration, 2018-2033
Table 14: Latin America Market Value (US$ Mn) Forecast by End-Users , 2018-2033
Table 15: Latin America Market Value (US$ Mn) Forecast by Distribution Channel, 2018-2033
Table 16: Europe Market Value (US$ Mn) Forecast by Country, 2018-2033
Table 17: Europe Market Value (US$ Mn) Forecast by Treatment Type, 2018-2033
Table 18: Europe Market Value (US$ Mn) Forecast by Route of Administration, 2018-2033
Table 19: Europe Market Value (US$ Mn) Forecast by End-Users , 2018-2033
Table 20: Europe Market Value (US$ Mn) Forecast by Distribution Channel, 2018-2033
Table 21: South Asia Market Value (US$ Mn) Forecast by Country, 2018-2033
Table 22: South Asia Market Value (US$ Mn) Forecast by Treatment Type, 2018-2033
Table 23: South Asia Market Value (US$ Mn) Forecast by Route of Administration, 2018-2033
Table 24: South Asia Market Value (US$ Mn) Forecast by End-Users , 2018-2033
Table 25: South Asia Market Value (US$ Mn) Forecast by Distribution Channel, 2018-2033
Table 26: East Asia Market Value (US$ Mn) Forecast by Country, 2018-2033
Table 27: East Asia Market Value (US$ Mn) Forecast by Treatment Type, 2018-2033
Table 28: East Asia Market Value (US$ Mn) Forecast by Route of Administration, 2018-2033
Table 29: East Asia Market Value (US$ Mn) Forecast by End-Users , 2018-2033
Table 30: East Asia Market Value (US$ Mn) Forecast by Distribution Channel, 2018-2033
Table 31: Oceania Market Value (US$ Mn) Forecast by Country, 2018-2033
Table 32: Oceania Market Value (US$ Mn) Forecast by Treatment Type, 2018-2033
Table 33: Oceania Market Value (US$ Mn) Forecast by Route of Administration, 2018-2033
Table 34: Oceania Market Value (US$ Mn) Forecast by End-Users , 2018-2033
Table 35: Oceania Market Value (US$ Mn) Forecast by Distribution Channel, 2018-2033
Table 36: MEA Market Value (US$ Mn) Forecast by Country, 2018-2033
Table 37: MEA Market Value (US$ Mn) Forecast by Treatment Type, 2018-2033
Table 38: MEA Market Value (US$ Mn) Forecast by Route of Administration, 2018-2033
Table 39: MEA Market Value (US$ Mn) Forecast by End-Users , 2018-2033
Table 40: MEA Market Value (US$ Mn) Forecast by Distribution Channel, 2018-2033
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 1: Global Market Value (US$ Mn) by Treatment Type, 2023-2033
Figure 2: Global Market Value (US$ Mn) by Route of Administration, 2023-2033
Figure 3: Global Market Value (US$ Mn) by End-Users , 2023-2033
Figure 4: Global Market Value (US$ Mn) by Distribution Channel, 2023-2033
Figure 5: Global Market Value (US$ Mn) by Region, 2023-2033
Figure 6: Global Market Value (US$ Mn) Analysis by Region, 2018-2033
Figure 7: Global Market Value Share (%) and BPS Analysis by Region, 2023-2033
Figure 8: Global Market Y-o-Y Growth (%) Projections by Region, 2023-2033
Figure 9: Global Market Value (US$ Mn) Analysis by Treatment Type, 2018-2033
Figure 10: Global Market Value Share (%) and BPS Analysis by Treatment Type, 2023-2033
Figure 11: Global Market Y-o-Y Growth (%) Projections by Treatment Type, 2023-2033
Figure 12: Global Market Value (US$ Mn) Analysis by Route of Administration, 2018-2033
Figure 13: Global Market Value Share (%) and BPS Analysis by Route of Administration, 2023-2033
Figure 14: Global Market Y-o-Y Growth (%) Projections by Route of Administration, 2023-2033
Figure 15: Global Market Value (US$ Mn) Analysis by End-Users , 2018-2033
Figure 16: Global Market Value Share (%) and BPS Analysis by End-Users , 2023-2033
Figure 17: Global Market Y-o-Y Growth (%) Projections by End-Users , 2023-2033
Figure 18: Global Market Value (US$ Mn) Analysis by Distribution Channel, 2018-2033
Figure 19: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2023-2033
Figure 20: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023-2033
Figure 21: Global Market Attractiveness by Treatment Type, 2023-2033
Figure 22: Global Market Attractiveness by Route of Administration, 2023-2033
Figure 23: Global Market Attractiveness by End-Users , 2023-2033
Figure 24: Global Market Attractiveness by Distribution Channel, 2023-2033
Figure 25: Global Market Attractiveness by Region, 2023-2033
Figure 26: North America Market Value (US$ Mn) by Treatment Type, 2023-2033
Figure 27: North America Market Value (US$ Mn) by Route of Administration, 2023-2033
Figure 28: North America Market Value (US$ Mn) by End-Users , 2023-2033
Figure 29: North America Market Value (US$ Mn) by Distribution Channel, 2023-2033
Figure 30: North America Market Value (US$ Mn) by Country, 2023-2033
Figure 31: North America Market Value (US$ Mn) Analysis by Country, 2018-2033
Figure 32: North America Market Value Share (%) and BPS Analysis by Country, 2023-2033
Figure 33: North America Market Y-o-Y Growth (%) Projections by Country, 2023-2033
Figure 34: North America Market Value (US$ Mn) Analysis by Treatment Type, 2018-2033
Figure 35: North America Market Value Share (%) and BPS Analysis by Treatment Type, 2023-2033
Figure 36: North America Market Y-o-Y Growth (%) Projections by Treatment Type, 2023-2033
Figure 37: North America Market Value (US$ Mn) Analysis by Route of Administration, 2018-2033
Figure 38: North America Market Value Share (%) and BPS Analysis by Route of Administration, 2023-2033
Figure 39: North America Market Y-o-Y Growth (%) Projections by Route of Administration, 2023-2033
Figure 40: North America Market Value (US$ Mn) Analysis by End-Users , 2018-2033
Figure 41: North America Market Value Share (%) and BPS Analysis by End-Users , 2023-2033
Figure 42: North America Market Y-o-Y Growth (%) Projections by End-Users , 2023-2033
Figure 43: North America Market Value (US$ Mn) Analysis by Distribution Channel, 2018-2033
Figure 44: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023-2033
Figure 45: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023-2033
Figure 46: North America Market Attractiveness by Treatment Type, 2023-2033
Figure 47: North America Market Attractiveness by Route of Administration, 2023-2033
Figure 48: North America Market Attractiveness by End-Users , 2023-2033
Figure 49: North America Market Attractiveness by Distribution Channel, 2023-2033
Figure 50: North America Market Attractiveness by Country, 2023-2033
Figure 51: Latin America Market Value (US$ Mn) by Treatment Type, 2023-2033
Figure 52: Latin America Market Value (US$ Mn) by Route of Administration, 2023-2033
Figure 53: Latin America Market Value (US$ Mn) by End-Users , 2023-2033
Figure 54: Latin America Market Value (US$ Mn) by Distribution Channel, 2023-2033
Figure 55: Latin America Market Value (US$ Mn) by Country, 2023-2033
Figure 56: Latin America Market Value (US$ Mn) Analysis by Country, 2018-2033
Figure 57: Latin America Market Value Share (%) and BPS Analysis by Country, 2023-2033
Figure 58: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023-2033
Figure 59: Latin America Market Value (US$ Mn) Analysis by Treatment Type, 2018-2033
Figure 60: Latin America Market Value Share (%) and BPS Analysis by Treatment Type, 2023-2033
Figure 61: Latin America Market Y-o-Y Growth (%) Projections by Treatment Type, 2023-2033
Figure 62: Latin America Market Value (US$ Mn) Analysis by Route of Administration, 2018-2033
Figure 63: Latin America Market Value Share (%) and BPS Analysis by Route of Administration, 2023-2033
Figure 64: Latin America Market Y-o-Y Growth (%) Projections by Route of Administration, 2023-2033
Figure 65: Latin America Market Value (US$ Mn) Analysis by End-Users , 2018-2033
Figure 66: Latin America Market Value Share (%) and BPS Analysis by End-Users , 2023-2033
Figure 67: Latin America Market Y-o-Y Growth (%) Projections by End-Users , 2023-2033
Figure 68: Latin America Market Value (US$ Mn) Analysis by Distribution Channel, 2018-2033
Figure 69: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023-2033
Figure 70: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023-2033
Figure 71: Latin America Market Attractiveness by Treatment Type, 2023-2033
Figure 72: Latin America Market Attractiveness by Route of Administration, 2023-2033
Figure 73: Latin America Market Attractiveness by End-Users , 2023-2033
Figure 74: Latin America Market Attractiveness by Distribution Channel, 2023-2033
Figure 75: Latin America Market Attractiveness by Country, 2023-2033
Figure 76: Europe Market Value (US$ Mn) by Treatment Type, 2023-2033
Figure 77: Europe Market Value (US$ Mn) by Route of Administration, 2023-2033
Figure 78: Europe Market Value (US$ Mn) by End-Users , 2023-2033
Figure 79: Europe Market Value (US$ Mn) by Distribution Channel, 2023-2033
Figure 80: Europe Market Value (US$ Mn) by Country, 2023-2033
Figure 81: Europe Market Value (US$ Mn) Analysis by Country, 2018-2033
Figure 82: Europe Market Value Share (%) and BPS Analysis by Country, 2023-2033
Figure 83: Europe Market Y-o-Y Growth (%) Projections by Country, 2023-2033
Figure 84: Europe Market Value (US$ Mn) Analysis by Treatment Type, 2018-2033
Figure 85: Europe Market Value Share (%) and BPS Analysis by Treatment Type, 2023-2033
Figure 86: Europe Market Y-o-Y Growth (%) Projections by Treatment Type, 2023-2033
Figure 87: Europe Market Value (US$ Mn) Analysis by Route of Administration, 2018-2033
Figure 88: Europe Market Value Share (%) and BPS Analysis by Route of Administration, 2023-2033
Figure 89: Europe Market Y-o-Y Growth (%) Projections by Route of Administration, 2023-2033
Figure 90: Europe Market Value (US$ Mn) Analysis by End-Users , 2018-2033
Figure 91: Europe Market Value Share (%) and BPS Analysis by End-Users , 2023-2033
Figure 92: Europe Market Y-o-Y Growth (%) Projections by End-Users , 2023-2033
Figure 93: Europe Market Value (US$ Mn) Analysis by Distribution Channel, 2018-2033
Figure 94: Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2023-2033
Figure 95: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023-2033
Figure 96: Europe Market Attractiveness by Treatment Type, 2023-2033
Figure 97: Europe Market Attractiveness by Route of Administration, 2023-2033
Figure 98: Europe Market Attractiveness by End-Users , 2023-2033
Figure 99: Europe Market Attractiveness by Distribution Channel, 2023-2033
Figure 100: Europe Market Attractiveness by Country, 2023-2033
Figure 101: South Asia Market Value (US$ Mn) by Treatment Type, 2023-2033
Figure 102: South Asia Market Value (US$ Mn) by Route of Administration, 2023-2033
Figure 103: South Asia Market Value (US$ Mn) by End-Users , 2023-2033
Figure 104: South Asia Market Value (US$ Mn) by Distribution Channel, 2023-2033
Figure 105: South Asia Market Value (US$ Mn) by Country, 2023-2033
Figure 106: South Asia Market Value (US$ Mn) Analysis by Country, 2018-2033
Figure 107: South Asia Market Value Share (%) and BPS Analysis by Country, 2023-2033
Figure 108: South Asia Market Y-o-Y Growth (%) Projections by Country, 2023-2033
Figure 109: South Asia Market Value (US$ Mn) Analysis by Treatment Type, 2018-2033
Figure 110: South Asia Market Value Share (%) and BPS Analysis by Treatment Type, 2023-2033
Figure 111: South Asia Market Y-o-Y Growth (%) Projections by Treatment Type, 2023-2033
Figure 112: South Asia Market Value (US$ Mn) Analysis by Route of Administration, 2018-2033
Figure 113: South Asia Market Value Share (%) and BPS Analysis by Route of Administration, 2023-2033
Figure 114: South Asia Market Y-o-Y Growth (%) Projections by Route of Administration, 2023-2033
Figure 115: South Asia Market Value (US$ Mn) Analysis by End-Users , 2018-2033
Figure 116: South Asia Market Value Share (%) and BPS Analysis by End-Users , 2023-2033
Figure 117: South Asia Market Y-o-Y Growth (%) Projections by End-Users , 2023-2033
Figure 118: South Asia Market Value (US$ Mn) Analysis by Distribution Channel, 2018-2033
Figure 119: South Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2023-2033
Figure 120: South Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023-2033
Figure 121: South Asia Market Attractiveness by Treatment Type, 2023-2033
Figure 122: South Asia Market Attractiveness by Route of Administration, 2023-2033
Figure 123: South Asia Market Attractiveness by End-Users , 2023-2033
Figure 124: South Asia Market Attractiveness by Distribution Channel, 2023-2033
Figure 125: South Asia Market Attractiveness by Country, 2023-2033
Figure 126: East Asia Market Value (US$ Mn) by Treatment Type, 2023-2033
Figure 127: East Asia Market Value (US$ Mn) by Route of Administration, 2023-2033
Figure 128: East Asia Market Value (US$ Mn) by End-Users , 2023-2033
Figure 129: East Asia Market Value (US$ Mn) by Distribution Channel, 2023-2033
Figure 130: East Asia Market Value (US$ Mn) by Country, 2023-2033
Figure 131: East Asia Market Value (US$ Mn) Analysis by Country, 2018-2033
Figure 132: East Asia Market Value Share (%) and BPS Analysis by Country, 2023-2033
Figure 133: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023-2033
Figure 134: East Asia Market Value (US$ Mn) Analysis by Treatment Type, 2018-2033
Figure 135: East Asia Market Value Share (%) and BPS Analysis by Treatment Type, 2023-2033
Figure 136: East Asia Market Y-o-Y Growth (%) Projections by Treatment Type, 2023-2033
Figure 137: East Asia Market Value (US$ Mn) Analysis by Route of Administration, 2018-2033
Figure 138: East Asia Market Value Share (%) and BPS Analysis by Route of Administration, 2023-2033
Figure 139: East Asia Market Y-o-Y Growth (%) Projections by Route of Administration, 2023-2033
Figure 140: East Asia Market Value (US$ Mn) Analysis by End-Users , 2018-2033
Figure 141: East Asia Market Value Share (%) and BPS Analysis by End-Users , 2023-2033
Figure 142: East Asia Market Y-o-Y Growth (%) Projections by End-Users , 2023-2033
Figure 143: East Asia Market Value (US$ Mn) Analysis by Distribution Channel, 2018-2033
Figure 144: East Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2023-2033
Figure 145: East Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023-2033
Figure 146: East Asia Market Attractiveness by Treatment Type, 2023-2033
Figure 147: East Asia Market Attractiveness by Route of Administration, 2023-2033
Figure 148: East Asia Market Attractiveness by End-Users , 2023-2033
Figure 149: East Asia Market Attractiveness by Distribution Channel, 2023-2033
Figure 150: East Asia Market Attractiveness by Country, 2023-2033
Figure 151: Oceania Market Value (US$ Mn) by Treatment Type, 2023-2033
Figure 152: Oceania Market Value (US$ Mn) by Route of Administration, 2023-2033
Figure 153: Oceania Market Value (US$ Mn) by End-Users , 2023-2033
Figure 154: Oceania Market Value (US$ Mn) by Distribution Channel, 2023-2033
Figure 155: Oceania Market Value (US$ Mn) by Country, 2023-2033
Figure 156: Oceania Market Value (US$ Mn) Analysis by Country, 2018-2033
Figure 157: Oceania Market Value Share (%) and BPS Analysis by Country, 2023-2033
Figure 158: Oceania Market Y-o-Y Growth (%) Projections by Country, 2023-2033
Figure 159: Oceania Market Value (US$ Mn) Analysis by Treatment Type, 2018-2033
Figure 160: Oceania Market Value Share (%) and BPS Analysis by Treatment Type, 2023-2033
Figure 161: Oceania Market Y-o-Y Growth (%) Projections by Treatment Type, 2023-2033
Figure 162: Oceania Market Value (US$ Mn) Analysis by Route of Administration, 2018-2033
Figure 163: Oceania Market Value Share (%) and BPS Analysis by Route of Administration, 2023-2033
Figure 164: Oceania Market Y-o-Y Growth (%) Projections by Route of Administration, 2023-2033
Figure 165: Oceania Market Value (US$ Mn) Analysis by End-Users , 2018-2033
Figure 166: Oceania Market Value Share (%) and BPS Analysis by End-Users , 2023-2033
Figure 167: Oceania Market Y-o-Y Growth (%) Projections by End-Users , 2023-2033
Figure 168: Oceania Market Value (US$ Mn) Analysis by Distribution Channel, 2018-2033
Figure 169: Oceania Market Value Share (%) and BPS Analysis by Distribution Channel, 2023-2033
Figure 170: Oceania Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023-2033
Figure 171: Oceania Market Attractiveness by Treatment Type, 2023-2033
Figure 172: Oceania Market Attractiveness by Route of Administration, 2023-2033
Figure 173: Oceania Market Attractiveness by End-Users , 2023-2033
Figure 174: Oceania Market Attractiveness by Distribution Channel, 2023-2033
Figure 175: Oceania Market Attractiveness by Country, 2023-2033
Figure 176: MEA Market Value (US$ Mn) by Treatment Type, 2023-2033
Figure 177: MEA Market Value (US$ Mn) by Route of Administration, 2023-2033
Figure 178: MEA Market Value (US$ Mn) by End-Users , 2023-2033
Figure 179: MEA Market Value (US$ Mn) by Distribution Channel, 2023-2033
Figure 180: MEA Market Value (US$ Mn) by Country, 2023-2033
Figure 181: MEA Market Value (US$ Mn) Analysis by Country, 2018-2033
Figure 182: MEA Market Value Share (%) and BPS Analysis by Country, 2023-2033
Figure 183: MEA Market Y-o-Y Growth (%) Projections by Country, 2023-2033
Figure 184: MEA Market Value (US$ Mn) Analysis by Treatment Type, 2018-2033
Figure 185: MEA Market Value Share (%) and BPS Analysis by Treatment Type, 2023-2033
Figure 186: MEA Market Y-o-Y Growth (%) Projections by Treatment Type, 2023-2033
Figure 187: MEA Market Value (US$ Mn) Analysis by Route of Administration, 2018-2033
Figure 188: MEA Market Value Share (%) and BPS Analysis by Route of Administration, 2023-2033
Figure 189: MEA Market Y-o-Y Growth (%) Projections by Route of Administration, 2023-2033
Figure 190: MEA Market Value (US$ Mn) Analysis by End-Users , 2018-2033
Figure 191: MEA Market Value Share (%) and BPS Analysis by End-Users , 2023-2033
Figure 192: MEA Market Y-o-Y Growth (%) Projections by End-Users , 2023-2033
Figure 193: MEA Market Value (US$ Mn) Analysis by Distribution Channel, 2018-2033
Figure 194: MEA Market Value Share (%) and BPS Analysis by Distribution Channel, 2023-2033
Figure 195: MEA Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023-2033
Figure 196: MEA Market Attractiveness by Treatment Type, 2023-2033
Figure 197: MEA Market Attractiveness by Route of Administration, 2023-2033
Figure 198: MEA Market Attractiveness by End-Users , 2023-2033
Figure 199: MEA Market Attractiveness by Distribution Channel, 2023-2033
Figure 200: MEA Market Attractiveness by Country, 2023-2033
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
